The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Positive results in proof-of-concept study to develop a vaccine against Streptococcus suis infection in pigs
Stockholm, April 25, 2022 – Intervacc AB (publ) announces positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with Streptococcus suis. The study showed that piglets from sows that had...Intervacc publishes the 2021 Annual Report
Stockholm, April 6, 2022 – Intervacc AB (publ) announces that the company’s 2021 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the...Strangvac, a vaccine against equine Strangles, released for sale in Sweden
Stockholm, March 23, 2022 – Intervacc announces today that the first batch of Strangvac®, a vaccine against equine Strangles, has been released for sale in Sweden. “Strangvac® has now been released and is in stock at our logistics partner in Sweden. The next...The European Medicines Agency extends the shelf life of the antigens used in Strangvac to 28 months
Stockholm, March 9, 2022 – The European Medicines Agency has today, after reviewing stability data, approved the extension of the shelf life of the antigens in Strangvac to 28 months. The manufacturing of Strangvac®, a vaccine against the highly contagious...Nyhetstjänster
